Guidelines in management of breast cancer UK experience

Document Sample
Guidelines in management of breast cancer UK experience Powered By Docstoc
					Guidelines in management of
breast cancer (UK experience)

Breast Pain (cyclical or not)
• No mass, mild pain:
  - <35 years: reassure and discharge.
  - > 35 years: mammography
• No mass, moderate to severe pain:
  - < 35: ultrasound
  - > 35: mammography
• Good support bra night and day, reduce caffeine
  intake, discontinue smoking, low fat diet,
  change the type of contraceptive pills and
• Evening primrose capsules:
   - Gamolenic acid 240-300mg
   - 3-4 months at least
   - Danazol 100mg daily, assess after one month
      and continue for 6 months if response.
 Cystic disease ( fibrocystic or
• Palpable cysts, 7% of western women.
• U/S, Mammography according to the
  age group.
• Aspirate (free hand or ultrasound):
 - No blood, no residual lump, not re-
  accumulating: discharge
 - Rapidly recurrent, or blood: re-image,
  FNAC ?excision?
• Multidisciplinary meeting (MDM).
 Breast Cancer : Diagnosis
• Monday am clinic (new patient): one
   stop (triple assessment).
• Wednesday pm: multidisciplinary
   meeting (MDM).
 - Surgeons, Oncologist, Radiologist,
   Pathologist, breast care nurses,
• Thursday am: New follow ups
• Thursday pm: all other follow ups
• Breast lump, asymmetric thickening, nodularity, nipple

• Triple assessment: clinical examination, radiological
  (ultrasound, mammography), Biopsy( wide bore needle,

• P value, U value, R value: 1-5(normal, benign, uncertain,
  suspicious, malignant).

• Any P3,U3, R3 should be biopsied.

• One stop clinic: patient will be given another appointment for
  the results if P3,U3,R3.

• FNAC is only used with too small or inaccessible lesions and
  with nipple discharge.

• All discordant results should be discussed in the MDM.
• Ultrasound: breast abnormalities in ages
  <35 years, however,
• It should not used in pain, and not as
  screening tool.
• Mammography:
    - Breast abnormalities in ages >35 years.
    - National screening programme >50
    - Early Screening (age < 50years,+family).
    - Nipple discharge.
    - Follow up in diagnosed breast cancer.

• Ill defined tumours/ breast
  conservative surgery.
• Multifocal disease?
• Assessment of the integrity of
  breast prosthesis?.
• Decision should be made at the
  MDM as mammography has
  taken over.
Excision biopsy

• Diagnostic uncertainty on core
  biopsy or FNAC.
• Lump >30mm in all age groups.
• Discuss and consider excision
  of all lumps in > 35 years even if
• MDM discretion
Breast Discharge
• Single duct:
• FNAC: performed by surgeons.
   - Benign (c2) or negative for blood:
     see 3 monthly for a year.
   - Uncertain (C3) or + ve for blood:
     consider surgery ( micro-
     dechoctomy <50 years, macro-
     dechoctomy>50 years).
Breast Discharge, continued
• Multiduct:
  - Bilateral: benign (c2) or negative for blood,
    reassure and discharge.
  - Unilateral: same criteria /follow up 3 monthly
    for a year.
  - Uncertain (C3) or + ve for blood, or
    troublesome: consider mammmo dechoctomy
    after discussion in MDM.

• Consider hyper prolactinaemia or drug induced
   galactorhea if profuse bilateral and
 Other investigation tools

• All patients should have FBC, LFT,
  CXR and bilateral mammogram.
• No routine bone scan or liver US for
  operable breast cancer unless
  abnormal routine tests or if
  symptoms suggestive of metastasis.

• D.C.I.S.
• Operable breast cancer.
• Locally advanced disease.
Non surgical treatment

•   Adjuvant chemotherapy.
•   Adjuvant hormone treatment.
•   Adjuvant Radiotherapy.
•   Neo-adjuvant Chemotherapy.
Male breast cancer

• <1% of breast cancer and < 1% of all
  male cancers.
• Guidelines are essentially the same
  as female breast cancer.
• Clinical outcome when matched for
  age, stage and treatment protocol
  are similar to females ( Perkins and
  Middleton BMJ 2003).
Surgery for early breast
• Non invasive breast cancer (DCIS):
   - No absolute consensus.
   - Lesions < 4cm: WLE with 1cm safety
     margin. No axillary surgery.
   - Lesions > 4cm or multifocal consider
   - Axillary node sampling if extensive multifocality
   (1-5% lymph node involvement) ( Dixon 1998)
   - DXT: beneficial
 - Hormonal treatment: less certain ( Lancet IBIS
   trial 2003).
• Lobular carcinoma in situ (LCIS): a marker lesion
   for increased risk of invasive cancer/close
WLE+ Augmentation
  Invasive Breast Cancer
• Breast Conservative Tumour (BCT):
  solitary <3cm, or selected cases with >
  3cm in large breast (MDM).
• Contraindications:
  - multifocal,
  - recurrent disease after BCT,
  - patient choice,
  - tumour > 3cm,
  - centrally placed tumors, or
  - if DXT is contraindicated,
  - pregnancy,
  - age< 35 years( MDM).
Breast Conservative Surgery
• A cylinder of breast tissue from skin to
  deep fascia is removed.
• No skin is removed unless superficial
• Macroscopic radial margins should be at
  least 10-20mm and microscopic margins at
  least 5mm.
• Radiopaque clips: 1( anterior
  surface),2(medial surface), 3(inferior
• Silk suture on tissues closest to nipple.
Breast conservative
What’s next
• Specimen x ray for all cases with a
  detectable mammographic abnormality.
• If close margin: immediate re-excision
  at same operation.
• 4 axillary node sampling if axillary
  clearance is not indicated.
• ER and PR status in all patients.
• Mark the cavity with 4 clips on the
  pectoral fascia for DXT( superior,
  inferior, medial and lateral).
 Treatment of axilla
• Incidence: 1%(DCIS),5%-28%(T1),
  48%(T2), 68%(T3), 88%(T4).
• Axillary sampling (4 node):
 - if clinically N0
• Axillary clearance: if N1 or +FNAC
  and if mastectomy is indicated for
  recurrent disease.
• Not indicated if previously treated
  with radiotherapy.
Locally advanced Breast

• large cancer(T3-4), skin or muscle or
  chest wall infiltration, matted L.N.
• Full screen for metastasis( bone
  scan, liver US, possible CT chest).
• MDM: select cases for adjuvant
  chemotherapy and hormonal ttt
  (Cancer;98:1150-60, 2003).
 Locally advanced Breast
• Hormonal: slowly growing, ER PR+,
  unfit patients for chemotherapy.
• Chemotherapy: inflammatory
  carcinoma, ER, PR –ve, young
  patient <35.
• Value: down staging,
• Definitive surgery will entirely
  depend on the tumor response.
• Adjuvant( in addition)/Neo-adjuvant (in
  advance/instead) of surgery.
• Details pathology: tumour size, grade,
  nodal, receptor status, margins of excision
  and the presence or absence of vascular or
  lymph-vascular invasion.
• Indications (risk factors): +ve nodes, grade
  2-3, size>2cm,vascular invasion and
  receptor –ve tumors.
• Anthracycline based e.g. 6 cycles of
  Epirubicin,5FU, Cyclophosphamide. Other
  combinations Epirubicin, Cyclophosphamide
  and Taxane.
 Chemotherapy continued
• HER2 receptor status is becoming
  increasingly important particularly in
  relapse patients who are candidates for
  Trastuzumab (Herceptin).
• The benefits of chemotherapy in
  postmenopausal patients is increasingly
  appreciated making the traditional
  classification of patients into pre and post
  menopausal less crucial.
• Chemotherapy is not routinely offered to
   Hormonal therapy
• All patients with estrogen/ progesterone
   receptors positive.
• Tamoxifen 20mg/day for 5 years.
• Exceptions: previous tamoxifen therapy or history of

• Should not simultaneously prescribed with DXT for fear of
  increased risk of pulmonary fibrosis. (Radiother Oncol
  2002,Br J Cancer 2004).

• Should not simultaneously prescribed with chemotherapy
  as it reduce its effect and significantly increase the
  incidence of thromboembolism.

• ATTOM trial 5 more years of tamoxifen after finishing a 5
  year treatment. Provided that the patients are disease free
  and had a complete resection of tumors.
   Arimidex (Anastrozole)
• A non steroidal aromatase inhibitor.
• ATTAC trial suggests: it is stronger
  with better prognosis and lesser
  side effects than tamoxifen.
• Nevertheless more arthralgia and
  fractures complication (Lancet
• Receptor +ve postmenopausal.
   Adjuvant Radiotherapy
• Post BCS: DXT is given to the breast and the
  lower axilla in the tangential glancing fields.

• DXT should be considered for all patients with
  completely excised DCIS who had undergone BCS.
• Only those with lesions <10mm should be
  discussed at the MDM.

• 4500-5000 cGY in 20-25 fractions daily. Options to
  give boost in younger patients.

• DXT to supraclav. L.N: Should be considered with
  4 or more pathologically involved axillary L.Ns,
  apical nodes involvement and with extra nodal
  spread of tumor.
Post-mastectomy Radiotherapy
 • Chest wall:
   - 4 or more pathologically involved axillary
   - primary tumor >5cm(large breast)
   - and tumor 3-5cm( small breast),
   - narrow deep margin <0.5cm,
   - evidence of lymph vascular invasion.
 • Irradiation to the axilla is only for those
   who have not had axillary clearance.
    Follow up
• Access to breast care nurse/unscheduled
  outpatient review and for post 5 years follow ups.

• Patients are seen for 5years in the breasts cancer
  follow up clinic starting from 2 weeks
  postoperative where the results are conducted.

• Alternating appointment every 3months between
  the oncologist and the surgeon for 2 years, then
  very 6 months for 3years.

• Clinical examination to the breast and the lymph
   Follow UP
• Mammography is requested annually for 5
• After 5 years if < 50years, arrange biennial
  mammography until 50years.
• if>50years then discharge to NHSBSP for
  3yearly screening.
• IF>70years self referral for 3yearly screening.
• All patients diagnosed with distant metastasis
  should stop mammography surveillance.
• Other investigations are only requested if
  symptoms develop e.g. back pain, lump, rash
Breast reconstruction

• Patients should be aware prior
  to surgery for the possibility of
  breast reconstruction.
• Primary? Delayed?
• All patients should be offered
  the opportunity to meet another
  patient who underwent BR.
Breast Reconstruction
Breast reconstruction
 Quality standards
• All patients with suspected breast
  cancer should be seen by specialist
  within 2 weeks of GP referral.
• More than 90% of GPs must receive
  feed back from the breast unit within
  one week of patients appointment.
• One stop clinic: Clinical, imaging,
  biopsy should be performed at the
  initial visit.
  Quality standards
• >90% of patients should be
  diagnosed preoperatively.
• <10% of patients should attend the
  hospital for more than one visit for
  diagnostic purposes.
• >90% of diagnosed patients should
  be admitted for surgery within 2
  weeks and 100% within 4 weeks.
• BCS, BCN, MDM are compulsory.
Outcome of breast cancer

• 60% of patients will develop some form of
  recurrence, 2/3(40%) will develop within 5

• 50% will eventually present with distant
  metastasis and die from the disease.

• Nottingham prognostic index (NPI):
  Grade(1-3)+ N Stage (N 0-2)(1-3)+ (0.2xsize
  of tumor in cm)
  Outcome of breast cancer

• No (negative axilla), N1 (low axilla},
  N2 (high axilla).
• Good (score<3.4)(80% 10 year
  survival ),moderate (score 3.4-
  5.4)(40% 10 year survival) , poor
  (score >5.4) (15%10 year survival).
• Example: 2cm,G2,N1= 0.4+2+2= 4.4
 Family history
• Genetic predisposition in 5-10%.
• However 15% of patients give family
• Pedigree analysis questionnaire and
  qualitative risk assessment will be
• Refer to regional genetic cancer
   Family History
• Risk factors: a close female relative had breast cancer <40,
  or had bilateral breast cancer or

• 2 close female had breast cancer < 60 or one had breast
  and the other had ovarian cancer or both had ovarian

• A male close relative had breast cancer at any age.

• A close relative denotes a first and second degree.

• Refer to regional cancer genetic clinic.

• Moderate and high risk female will have an annual clinical
  assessment and mammography starting from the age of 35-
  40 years.
• At 50 years they are discharged back to the NHSBSP
Thank you

Shared By: